Investor/Media Information

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015

October 19, 2017: Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 16, 2017: Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

October 16, 2017: Abeona Therapeutics Announces Public Offering of Common Stock

October 16, 2017: Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies

October 11, 2017: Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA

October 6, 2017: Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa

October 4, 2017: Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

September 28, 2017: Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

September 22, 2017: Abeona Therapeutics Announces Upcoming Conference Participation

August 29, 2017: Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

August 17, 2017: Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

August 15, 2017: Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

July 25, 2017: Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer

July 18, 2017: Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

June 29, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

June 2, 2017: Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

May 30, 2017: Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 19, 2017: Abeona Therapeutics to Present at Multiple Upcoming Conferences

May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

May 12, 2017: Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT

May 9, 2017: Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA

May 8, 2017: Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting

May 2, 2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference

April 25, 2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting

April 20, 2017: Abeona to Present At Multiple Upcoming Conferences

April 5, 2017: Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences

March 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights

March 13, 2017: Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences

March 8, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

March 7, 2017: Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference

March 3, 2017: Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai

February 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit

February 21, 2017: Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress

February 17, 2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017

February 7, 2017: Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017

February 1, 2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A

January 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

January 17, 2017: Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017

January 3, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease

Press Releases

Stay up to date with the latest news from Abeona Therapeutics.
Read Press Releases »

Events & Presentations

Watch past webcasts, listen to conference calls, and view a schedule of events.
View Materials »

Stock Information

Everything you need to know about Abeona’s stock history and analysis.
View Stock Information »

Financial Information

View all of Abeona’s SEC filings, quarterly reports, and other pertinent documents.
View Financial Information »

Corporate Governance

Learn about Abeona’s Board of Directors, Code of Ethics, and Governing Guidelines.
Learn More »

Contact Information

Get in touch about investments and business collaborations.
Contact Us »